These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 7261076)

  • 21. Significance of pentraxin-3 in patients with juvenile scleroderma.
    Adrovic A; Sahin S; Barut K; Durmus S; Uzun H; Kasapcopur O
    Clin Exp Rheumatol; 2017; 35 Suppl 106(4):221-222. PubMed ID: 28664833
    [No Abstract]   [Full Text] [Related]  

  • 22. Circulating levels of soluble CD30 are increased in patients with localized scleroderma and correlated with serological and clinical features of the disease.
    Ihn H; Yazawa N; Kubo M; Yamane K; Sato S; Fujimoto M; Kikuchi K; Soma Y; Tamaki K
    J Rheumatol; 2000 Mar; 27(3):698-702. PubMed ID: 10743811
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Autoantibodies against calpastatin in sera from patients with systemic sclerosis.
    Sato S; Hasegawa M; Nagaoka T; Takamatsu Y; Yazawa N; Ihn H; Kikuchi K; Takehara K
    J Rheumatol; 1998 Nov; 25(11):2135-9. PubMed ID: 9818655
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Serum immunoglobulins in selected disease entities].
    Gibowski M; Burda A
    Przegl Dermatol; 1976; 63(2):129-32. PubMed ID: 1265301
    [No Abstract]   [Full Text] [Related]  

  • 25. Clinical significance of serum levels of soluble interleukin-2 receptor in patients with localized scleroderma.
    Ihn H; Sato S; Fujimoto M; Kikuchi K; Takehara K
    Br J Dermatol; 1996 May; 134(5):843-7. PubMed ID: 8736323
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Electrophoretic studies on serum proteins in scleroderma in the course of the disease and during the treatment].
    HUBSCHMANN K; STAVA Z
    Cesk Dermatol; 1954 Dec; 29(6):347-53. PubMed ID: 14364582
    [No Abstract]   [Full Text] [Related]  

  • 27. [HLA antigen frequencies in patients with progressive systemic sclerosis and morphea (author's transl)].
    Freudenberg J; Holzmann H; Schneider S; Korting GW
    Arch Dermatol Res; 1978 Nov; 263(2):197-205. PubMed ID: 736604
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum renin and renin substrate levels in scleroderma.
    Fleischmajer R; Gould AB
    Proc Soc Exp Biol Med; 1975 Nov; 150(2):374-9. PubMed ID: 1208551
    [No Abstract]   [Full Text] [Related]  

  • 29. SERUM PROTEINS AND GLYCOPROTEINS IN SCLERODERMA.
    FLEISCHMAJER R
    Arch Dermatol; 1964 May; 89():749-53. PubMed ID: 14122109
    [No Abstract]   [Full Text] [Related]  

  • 30. [Immunologic findings in scleroderma in childhood].
    Stögmann W
    Monatsschr Kinderheilkd (1902); 1979 May; 127(5):308-10. PubMed ID: 460236
    [No Abstract]   [Full Text] [Related]  

  • 31. [Electrophoretic and immunoelectrophoretic analysis of serum proteins in 30 patients with xeroderma pigmentosum].
    Marill FG; Irunberry J; Hamra-Krouha MS
    Bull Soc Fr Dermatol Syphiligr; 1971; 78(2):109-13. PubMed ID: 5128240
    [No Abstract]   [Full Text] [Related]  

  • 32. [Rheological and coagulative blood properties in patients with systemic scleroderma undergoing hyperbaric oxygenation in combined treatment].
    Iakunin GA; Grebenev AL; Lukich VL; Smolianitskiĭ AIa; Grabskiĭ MA
    Ter Arkh; 1983; 55(7):120-4. PubMed ID: 6623377
    [No Abstract]   [Full Text] [Related]  

  • 33. Autoantibodies to HMG-17 nucleosomal protein in patients with scleroderma.
    Vlachoyiannopoulos PG; Boumba VA; Tzioufas AG; Seferiadis C; Tsolas O; Moutsopoulos HM
    J Autoimmun; 1994 Apr; 7(2):193-201. PubMed ID: 8037838
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Localized scleroderma and PSS specific anti-Og antibody (author's transl)].
    Nishikawa T; Kurihara S; Sugiura M; Shimizu H; Tojo T
    Nihon Hifuka Gakkai Zasshi; 1981 Jul; 91(8):859-60. PubMed ID: 6976462
    [No Abstract]   [Full Text] [Related]  

  • 35. Clinical significance of surfactant protein D as a serum marker for evaluating pulmonary fibrosis in patients with systemic sclerosis.
    Asano Y; Ihn H; Yamane K; Yazawa N; Kubo M; Fujimoto M; Tamaki K
    Arthritis Rheum; 2001 Jun; 44(6):1363-9. PubMed ID: 11407696
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serologic alterations in scleroderma and sclerodermatomyositis.
    Clark JA; Winkelmann RK; Ward LE
    Mayo Clin Proc; 1971 Feb; 46(2):104-7. PubMed ID: 4100586
    [No Abstract]   [Full Text] [Related]  

  • 37. [Scleropathy].
    EMMRICH R
    Z Gesamte Inn Med; 1952 Nov; 7(21):987-95. PubMed ID: 13029643
    [No Abstract]   [Full Text] [Related]  

  • 38. Immunoglobulins in systemic scleroderma.
    Spencer SK; Winkelmann RK
    Mayo Clin Proc; 1971 Feb; 46(2):108-10. PubMed ID: 4100587
    [No Abstract]   [Full Text] [Related]  

  • 39. Expression of CD1a and CD86 on scleroderma Langerhans cells.
    Xie Y; Zhang X; Inoue Y; Wakasugi S; Makino T; Ihn H
    Eur J Dermatol; 2008; 18(1):50-4. PubMed ID: 18086589
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Pulmonary carcinoma in patients with sclerodermia (author's transl)].
    Raković J; Rebić P
    Plucne Bolesti Tuberk; 1979; 31(3-4):164-8. PubMed ID: 538121
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.